Clinical Trial Update: NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN [Phase 3]

View source ↗

Summary

Phase 3 trial update for NIVolumab in recurrent/metastatic platinum-refractory squamous cell carcinoma of the head and neck has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Gruppo Oncologico del Nord-Ovest | Conditions: Squamous Cell Carcinoma of Head and Neck | Phase 3 | Status: COMPLETED